Latest News

• share
• favorite_border

Since 1970, health care professionals have convened at the Society of Gynecologic Oncology (SGO)’s Annual Meeting on Women’s Cancer® to discuss the latest in gynecologic cancer care and science, receive educational programming, and network. Members of the entire gynecologic cancer care team who provide treatment and care in the areas of chemotherapy, radiation therapy, surgery, and palliative care attend the SGO Annual Meeting.

• share
• favorite_border

The Foundation for Women’s Cancer (FWC) is pleased to host a free Patient and Advocate Education Forum on​​ Friday, March 15, 2024, 10 a.m. – 4:30 p.m. PT, in San Diego, CA, at the San Diego Convention Center. The organization welcomes all gynecologic cancer (cervical, endometrial/uterine, ovarian, vaginal, and vulvar) patients, advocates, family members, and providers.

• share
• favorite_border

The results of two clinical trials, presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showcased adding immunotherapy to standard chemotherapy resulted in significantly longer progression-free survival (PFS) among patients with advanced or recurrent endometrial cancer (EC).

• share
• favorite_border

After resolving missing data burdens, the ENGOT-OV16/NOVA (NCT01847274) study data shows no difference in overall survival for platinum-sensitive recurrent ovarian cancer (PSROC) patients who received PARP inhibitor niraparib maintenance therapy (MT) and those who did not. Results from the trial were presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute.

• share
• favorite_border

Time-related and financial burdens are detrimental to gynecologic cancer patient and survivor quality of life (QOL), according to two research studies presented yesterday and today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.

• share
• favorite_border

Clinical trial participation was associated with improved overall survival (OS) compared to standard of care therapy among women with platinum-resistant epithelial ovarian cancer (EOC), according to a research study presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.

• share
• favorite_border

Administering PARP inhibitor (PARPi) olaparib prior to surgical intervention and chemotherapy in ovarian cancer patients – a new approach – is feasible and resulted in favorable surgical options, managed adverse events, and positive health outcomes, according to results from the Neoadjuvant Olaparib Window (NOW) Trial presented today by Shannon Westin, MD et al. at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.

• share
• favorite_border

The Foundation for Women’s Cancer will host a Patients and Advocates Education Forum and Luncheon on Friday, March 24, 2023 in Tampa, FL during the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer.

• share
• favorite_border

The Foundation for Women’s Cancer (FWC), the official foundation of the Society for Gynecologic Oncology (SGO), is pleased to announce the hiring of Holly Gibout as Chief Development Officer. Holly joined the foundation’s team on November 28, 2022.